Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State

Background: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe thrombotic thrombocytopenia that predominantly occurs after adenoviral vector-based vaccines. VITT patients produce anti-platelet factor 4 (PF4) antibodies with restricted clonality (i.e., mono/oligoclonal) with lambda light chains. Long-term follow-up studies in VITT show a disconnect in the persistence of anti-PF4 antibodies, whereby ELISA-positive antibodies persist significantly longer than platelet-activating antibodies. The mechanistic basis of this is unclear and could be explained by a couple of hypotheses: (1) Epitope spreading where, with time, the specificity of platelet-activating anti-PF4 antibodies may “spread” to recognize only PF4 complexed to heparin vs. (2) Persistence of clonally restricted platelet-activating anti-PF4 antibodies which decrease in titers with time such that their levels are insufficient to crosslink platelet FcGRIIa and induce platelet activation.

Methods: Acute, convalescent patient sera and affinity-purified anti-PF4 antibodies were evaluated in antigen-based, functional (platelet-activation-based), and mass spectrometry studies as previously described (Blood, 2022 Jul 7;140(1):73-77). The median time to last follow-up was 243 days after the acute episode (range: 114-664 days).

Results: Follow-up samples were obtained from 6 VITT patients after Ad26.COV2.S vaccination. At last follow-up, anti-PF4 IgG antibodies reactive in PF4/polyanion ELISA were detected in the sera of 5/6 VITT patients. However, only one of these samples stimulated platelet activation in the PF4-dependent P-selectin expression assay (PEA; 199 days after acute presentation). Affinity-purified anti-PF4 antibodies were detected by ELISA in all follow-up samples and three of the six affinity-purified anti-PF4 antibody samples activated platelets in the PEA. Four of the six VITT patients demonstrated a monoclonal anti-PF4 antibody, while one each had a biclonal and triclonal profile. Five VITT patients produced IgG lambda light chain antibodies, while one produced an IgG kappa. All six VITT patients demonstrated synonymous anti-PF4 antibody profiles when comparing acute and follow-up antibody repertoires, without evidence of VITT patients producing new anti-PF4 antibodies after the acute episode. In all cases, levels of anti-PF4 antibodies were significantly lower in convalescent samples relative to acute samples. Given this data on the persistence of clonally-restricted VITT antibodies, samples from another VITT patient with thrombocytopenia (100-150,000/uL) persisting for more than three years were similarly evaluated. This patient, who experienced severe thrombosis after ChAdOx1 nCoV19 vaccination, demonstrated persistent ELISA and PEA positivity even three years after symptom onset but had not experienced breakthrough thrombosis while on anticoagulation therapy. Serum protein electrophoresis (SPEP) did not detect a monoclonal gammopathy. Anti-PF4 antibodies immuno-enriched from a sample obtained >2 years after acute presentation demonstrated a monoclonal profile. While non-availability of an acute sample for anti-PF4 antibody characterization precluded a firm determination of whether this “Long VITT” case represented a subset of monoclonal gammopathy of thrombotic significance (MGTS; Blood 2023 Apr 6;141(14):1772-1776; New Eng J Med 2024 Aug 8), the chronicity of thrombocytopenia, presence of a monoclonal anti-PF4 antibody and persistently positive anti-PF4 serology supports this diagnosis.

Conclusions. Clonally-restricted VITT antibodies persist for months-years with no evidence for the production of novel anti-PF4 antibodies after the acute event. Decreased abundance of anti-PF4 antibodies leads to negative functional results with follow up samples. Some platelet-activating antibodies can persist for very long periods (>3 years) and mediate persistent thrombocytopenia, representing an SPEP-negative MGTS-like state. This study also demonstrates the first example of a VITT antibody with a kappa light chain. The requirement for anticoagulation in patients demonstrating ELISA-positive/functional test-negative results is not clear, but the persistence of mono/oligoclonal anti-PF4 antibodies raises the possibility for the upregulation of pathogenic antibody production in proinflammatory settings.

Wool:Diagnostica Stago: Honoraria, Membership on an entity's Board of Directors or advisory committees. Abou-Ismail:Sanofi: Honoraria; Takeda: Honoraria. Murray:The Binding Site: Patents & Royalties: Intellectual Property Rignts Licensed with potential royalties. Pabmanabhan:Retham technologies, Mayo Clinic, Versiti: Divested equity in a private or publicly-traded company in the past 24 months, Other: Officer, Patents & Royalties.